Feb 2, 2009 - EpiCept Corporation announced today that the U.S. FDA indicated that the Company has the necessary pivotal data to file a New Drug Application for Ceplene (histamine dihydrochloride) in conjunction with interleukin-2 (IL-2) as a remission maintenance treatment of acute myeloid leukemia (AML).
The details can be read here.
No comments:
Post a Comment